Xaluprine 20 mg/ml, Suspension zum Einnehmen

7680653710018 CH-65371 suspension
Xaluprine 20 mg/ml, Suspension zum Einnehmen
Xaluprine 20 mg/ml, Suspension zum Einnehmen
Xaluprine 20 mg/ml, Suspension zum Einnehmen
1 / 3
google

Article details

Package size
100
Selling units
100
Measure
ml
Galenic form
suspension
Galenic group
unbekannt

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Patient information leaflet
Allemand
23/06/2026
Patient information leaflet
Français
23/06/2026
Patient information leaflet
Italien
23/06/2026
Summary of Product Characteristics
Allemand
23/06/2026
Summary of Product Characteristics
Français
23/06/2026
Summary of Product Characteristics
Italien
23/06/2026

Detailed composition

Substance Quantity Type Category
mercaptopurinum monohydricum
20.0 MG Substance Wirkstoff (Principe actif)
xanthani gummi
- Substance HNIDK
aspartamum
3.0 MG Substance HBESI
rubi idaei succus concentratus
- Substance HNIDK
saccharum
- Substance HBESI
E 220
- Substance HBESI
E 219
1.15 MG Substance HBESI
E 215
0.57 MG Substance HBESI
E 202
- Substance Konservierungsstoff (Conservateur)
natrii hydroxidum
- Substance HNIDK
aqua purificata
- Substance HNIDK
natrium
- Substance HBESI

Reimbursement information

Public price
CHF 292.00
Specialties list
Yes
Generic
No

Reimbursement limitation

SL addition date: 01/06/2025

Authorization holder

Lipomed AG

4144 Arlesheim

Authorization information

Swissmedic authorization number
65371
Drug name
Xaluprine 20 mg/ml, Suspension zum Einnehmen
Galenic form
SUOR
ATC Code
L01BB02
Authorization status
Z
Dispensing category
A
First authorization
18/12/2014
Authorization expiration date
31/12/9999
IT Number
07.16.1.
Domain
Human medicine
Field of application
Zytostatikum

Package details

Description (FR)
XALUPRINE susp 20 mg/ml fl 100 ml
Description (DE)
XALUPRINE Susp 20 mg/ml Fl 100 ml
Market launch
18/12/2014
Narcotic (BTM)
No
Buy us a coffee Explore the data